Evaluation of the implication of KIR2DL2 receptor in multiple sclerosis and herpesvirus susceptibility

Journal of Neuroimmunology

Volumn 271, Issue 1-2, 2014, Pages 30-35

  Ben Fredj, Nadia ^a   Rizzo, Roberta ^b   Bortolotti, Daria ^b   Nefzi, Faten ^a   Chebel, Saber ^c   Rotola, Antonella ^b   Frih Ayed, Mahbouba ^c   Di Luca, Dario ^b   Aouni, Mahjoub ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITY OF FERRARA   (Italy)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

Human herpesviruses; KIR2DL2; Multiple sclerosis

Indexed keywords

GENOMIC DNA; HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEMALE; GENE AMPLIFICATION; GENE INTERACTION; GENOTYPE; HAPLOTYPE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; INFECTION RISK; INFECTION SENSITIVITY; KIR2DL2 GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUNISIA; VARICELLA ZOSTER VIRUS;

HUMAN HERPESVIRUSES; KIR2DL2; MULTIPLE SCLEROSIS;

ADULT; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HERPES SIMPLEX; HLA-C ANTIGENS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, KIR2DL2; SIMPLEXVIRUS; YOUNG ADULT;

EID: 84900470076     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.03.017     Document Type: Article

References (53)

1. Ascherio A., Munger K.L. Environmental risk factor for multiple sclerosis. Part I: role of infection. Ann. Neurol. 2007, 61:288-299.
2. Ben Fredj N., Rotola A., Nefzi F., Chebel S., Rizzo R., Caselli E., Frih-Ayed M., Di Luca D., Aouni M. Identification of human herpesviruses 1 to 8 in Tunisian multiple sclerosis patients and healthy blood donors. J. Neurovirol. 2012, 18:12-19.
3. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., McFarland H., Henkart P.A., Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5941-5946.
4. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17:189-220.
5. Boyton R.J., Altmann D.M. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 2007, 149:1-8.
6. Burgoon M.P., Cohrs R.J., Bennett J.L., Anderson S.W., Ritchie A.M., Cepok S., Hemmer B., Gilden D., Owens G.P. Varicella zoster virus is not a diseaserelevant antigen in multiple sclerosis. Ann. Neurol. 2009, 65:474-479.
7. Carrol M.C., Prodeus A.P. Linkages of innate and adaptive immunity. Curr. Opin. Immunol. 1998, 10:36-40.
8. Caselli E., Rizzo R., Ingianni A., Contini P., Pompei R., Di Luca D. High prevalence of HHV8 infection and specific killer cell immunoglobulin-like receptors allotypes in Sardinian patients with type 2 diabetes mellitus. J. Med. Virol. 2013, (2013 Sep 30). 10.1002/jmv.23771.
9. Casetta I., Granieri E. Clinical infections and multiple sclerosis: contribution from analytical epidemiology. J. Neurovirol. 2000, 6:S147-S151.
10. Colonna M., Navarro F., Bellon T., Llano M., Garcia P., Samaridis J., Angman L., Cella M., López-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 1997, 186:1809-1818.
11. Das M.P., Nicholson L.B., Greer J.M., Kuchroo V.K. Autopathogenic T helper cell type 1 (Th1) and protective Th2 clones differ in their recognition of the autoantigenic peptide of myelin proteolipid protein. J. Exp. Med. 1997, 186:867-876.
12. Diefenbach A., Raulet D.H. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 2002, 188:9-21.
13. Du Z., Gjertson D.W., Reed E.F., Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics. 2007, 59:1-15.
14. Dupont B., Hsu K.C. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr. Opin. Immunol. 2004, 16:634-643.
15. Estefanía E., Gómez-Lozano N., Portero F., de Pablo R., Solís R., Sepúlveda S., Vaquero M., González M.A., Suárez E., Roustán G., Vilches C. Influence of KIR gene diversity on the course of HSV-1 infection: resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2. Tissue Antigens. 2007, 70:34-41.
16. Fan Q.R., Long E.O., Wiley D.C. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat. Immunol. 2001, 2:452-460.
17. Ferrante P., Mancuso R., Pagani E., Guerini F.R., Calvo M.G., Saresella M., Speciale L., Caputo D. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack. J. Neurovirol. 2000, 6:S109-S114.
18. Fotheringham J., Jacobson S. Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes. 2005, 12:4-9.
19. French A.R., Yokoyama W.M. Natural killer cells and viral infections. Curr. Opin. Immunol. 2003, 15:45-51.
20. Fusco C., Guerini F.R., Nocera G., Ventrella G., Caputo D., Valentino M.A., Agliardi C., Gallotti J., Morra V.B., Florio C., Clerici M., Lombardi M.L. KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J. Neuroimmunol. 2010, 229:232-237.
21. Gandhi R., Laroni A., Weiner H.L. Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2010, 221:7-14.
22. García-Leóna J.A.A., Pinto-Medela M.J., García-Trujillo L., López-Gómeza C., Oliver-Martosa B., Prat-Arrojoc I., Marín-Banascoa C., Suardíaz-Garcíaa M., Maldonado-Sancheza R., Fernández-Fernández O., Leyva-Fernándeza L. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol. Immunol. 2011, 48:1896-1902.
23. Gumperz J.E., Litwin V., Phillips J.H., Lanier L.L., Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 1995, 181:1133-1144.
24. Hao J., Liu R., Piao W., Zhou Q., Vollmer T.L., Campagnolo D.I., Xiang R., La Cava A., Van Kaer L., Shi F.D. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 2010, 207:1907-1921.
25. Hawkes C.H., Giovannoni G., Keir G., Cunnington M., Thompson E.J. Seroprevalence of herpes simplex virus type 2 in multiple sclerosis. Acta Neurol. Scand. 2006, 114:363-367.
26. Hohlfeld R., Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 2004, 2:14599-14606.
27. Kastrukoff L.F., Morgan N.G., Zecchini D., White R., Petkau A.J., Satoh J., Paty D.W. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Neurology 1999, 52:351-359.
28. Kumar V., McNerney M.E. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat. Rev. Immunol. 2005, 5:363-374.
29. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
30. Lorentzen A.R., Karlsen T.H., Olsson M., Smestad C., Mero I.L., Woldseth B., Sun J.Y., Senitzer D., Celius E.G., Thorsby E., Spurkland A., Lie B.A., Harbo H.F. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann. Neurol. 2009, 65:658-666.
31. Mancuso R., Delbue S., Borghi E., Pagani E., Calvo M.G., Caputo D., Granieri E., Ferrante P. Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. J. Med. Virol. 2007, 79:192-199.
32. Marrie R.A. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004, 3:709-718.
33. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., Van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001, 50:121-127.
34. Mirandola P., Stefan A., Brambilla E., Campadelli-Fiume G., Grimaldi L.M. Absence of human herpes virus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology 1999, 53:1367-1368.
35. Moraru M., Cisneros E., Gómez-Lozano N., de Pablo R., Portero F., Cañizares M., Vaquero M., Roustán G., Millán I., López-Botet M., Vilches C. Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity. J. Immunol. 2012, 188:4412-4420.
36. Moretta L., Bottino C., Pende D., Vitale M., Mingari M.C., Moretta A. Different checkpoints in human NK-cell activation. Trends. Immunol. 2004, 25:670-676.
37. Negishi K., Waldeck N., Chandy G., Buckingham B., Kershnar A., Fisher L., Gupta S., Charles M.A. Natural killer and islet killer cell activities in type 1 (insulin dependent) diabetes. Diabetologia 1986, 29:352-357.
38. Olivares-Villagomez D., Wang Y., Lafaille J.J. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 1998, 188:1883-1894.
39. Parham P., McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat. Rev. Immunol. 2003, 3:108-122.
40. Rizzo R., Gentili V., Casetta I., Caselli E., De Gennaro R., Granieri E., Cassai E., Di Luca D., Rotola A. Altered natural killer cells' response to herpes virus infection in multiple sclerosis involves KIR2DL2 expression. J. Neuroimmunol. 2012, 251:55-64.
41. Rodríguez Carnero S., Martínez-Vázquez C., Potel Alvarellos C., Alvarez Fernández M., Prieto González J.M., Noya García M., de la Fuente Aguado J., Sopeña Argüelles B. Lack of human herpes virus type 6 DNA in CSF by nested PCR among patients with multiple sclerosis. Rev. Clin. Esp. 2002, 202:588-591.
42. Rotola A., Merlotti I., Caniatti L., Caselli E., Granieri E., Tola M.R., Di Luca D., Cassai E. Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease. Mult. Scler. 2004, 10:348-354.
43. Saraste M., Irjala H., Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 2007, 28:121-126.
44. Sargsyan S.A., Shearer A.J., Ritchie A.M., Burgoon M.P., Anderson S., Hemmer B., Stadelmann C., Gattenlöhner S., Owens G.P., Gilden D., Bennett J.L. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010, 74:1127-1135.
45. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., Andreoni L., Trivedi P., Salvetti M., Faggioni A., Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007, 204:2899-2912.
46. Shi F.D., Van K.L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat. Rev. Immunol. 2006, 6:751-760.
47. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
48. Takahashi K., Aranami T., Endoh M., Miyake S., Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004, 127:1917-1927.
49. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., Tyan D., Lanier L.L., Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
50. Wandinger K., Jabs W., Siekhaus A., Bubel S., Trillenberg P., Wagner H., Wessel K., Kirchner H., Hennig H. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000, 55:178-184.
51. Wolf S.D., Dittel B.N., Hardardottir F., Janeway C.A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 1996, 184:2271-2278.
52. Yen J.H., Moore B.E., Nakajima T., Scholl D., Schaid D.J., Weyand C.M., Goronzy J.J. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J. Exp. Med. 2001, 193:1159-1167.
53. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186:1677-1687.